|
JPS57106673A
(en)
|
1980-12-24 |
1982-07-02 |
Chugai Pharmaceut Co Ltd |
Dibenzo(b,f)(1,4)oxazepin derivative
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20050089932A1
(en)
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
WO2005040229A2
(en)
|
2003-10-24 |
2005-05-06 |
Avidia, Inc. |
Ldl receptor class a and egf domain monomers and multimers
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン，エルエルシー |
抗体製剤
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
CN101898945B
(zh)
|
2010-07-27 |
2013-05-08 |
大连理工大学 |
盐析萃取发酵液中丙酮和丁醇的方法
|
|
ES2612914T3
(es)
|
2011-03-31 |
2017-05-19 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos dirigidos contra Icos y usos de los mismos
|
|
EP2892928B1
(en)
|
2012-09-03 |
2018-05-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies directed against icos for treating graft-versus-host disease
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
TWI719970B
(zh)
|
2015-03-23 |
2021-03-01 |
美商永斯醫療股份有限公司 |
針對ｉｃｏｓ之抗體
|
|
EA201792184A1
(ru)
*
|
2015-04-01 |
2018-04-30 |
Анаптисбайо, Инк. |
Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
WO2018025221A1
(en)
*
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
AU2017321625A1
(en)
*
|
2016-08-30 |
2019-04-04 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP7290568B2
(ja)
*
|
2016-12-20 |
2023-06-13 |
カイマブ・リミテッド |
癌免疫療法のための併用療法での多重特異性抗体
|
|
MX2019008208A
(es)
|
2017-01-09 |
2019-12-11 |
Tesaro Inc |
Métodos para tratar el cáncer con anticuerpos anti-tim-3.
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
EP3615572A1
(en)
*
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
EP3634483A1
(en)
*
|
2017-06-09 |
2020-04-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
TWI852940B
(zh)
*
|
2018-09-04 |
2024-08-21 |
美商泰沙羅公司 |
治療癌症之方法
|